Celltrion, Inc. is a prominent player in the Healthcare sector, specifically within the Biotechnology industry. As a leading biopharmaceutical company, it commands a significant market presence with a current market capitalization of 40.68 Trillion KRW. The company focuses on the development and commercialization of biosimilars and innovative drugs, making it a key name for investors monitoring advancements in medical treatments and therapies.

From a technical standpoint, Celltrion currently receives a Strong Sell rating with a total score of -4. This negative outlook is primarily driven by a strong long-term bearish trend, as the current price is trading below its 200-day Simple Moving Average (SMA), contributing -2 points to the score. This is further compounded by bearish signals from momentum and volume indicators. The MACD histogram is negative, indicating sustained downward momentum (-1 point), and the On-Balance Volume (OBV) is below its moving average, suggesting distribution or selling pressure (-1 point). The ADX indicator at 21.5 suggests the trend is not yet considered strong, and the RSI is in neutral territory, providing no immediate counter-signals.

The strong bearish technical rating appears in a context of limited fundamental clarity. Key valuation metrics like the P/E ratio are currently unavailable, and the provided dividend yield of 40.0 appears unusually high, which could be a data anomaly or a red flag warranting further investigation. Furthermore, with no recent EPS data and the next earnings report scheduled far in the future on 29/10/2026, investors lack near-term catalysts or fundamental data points to challenge the prevailing technical weakness. Given the dominant bearish indicators and sparse fundamental information, the technical analysis suggests a cautious approach is warranted.